Health · 1 view
Drug tapering noninferior to treatment continuation for rheumatoid arthritis with low disease activity
For patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA), structured tapering of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is noninferior to treatment continuation for…
Summary
For patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA), structured tapering of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is noninferior to treatment continuation for maintaining disease control over 24 weeks, according to a study published online Oct. 6 in Arthritis & Rheumatology .
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Protein clues may help explain heart disease risk that persists despite lower LDL cholesterolContinue reading
- GLP-1 treatment linked to lower risk of hospitalization and death in older adults with fatty liver diseaseContinue reading
- Early axial spondyloarthritis diagnosis linked to lower long-term spinal damageContinue reading
- Toddler EEG study shows why story time and playtime really matterContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow